Bernstein Rates Nuvalent (NUVL) hold, $124 Price Target
Bernstein adjusted its outlook on Nuvalent, Inc., lowering its rating and reducing the price target to $124 on June 24, 2026, a 0.35% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Bernstein rated Nuvalent, Inc. ($NUVL) "hold" with a $124 price target on June 24, 2026.
NUVL
Nuvalent, Inc.
Key Points
- Bernstein downgraded Nuvalent, Inc. (NUVL) to a market perform rating on June 24, 2026.
- Bernstein's $124 price target implies 0.35% upside from Nuvalent, Inc.'s ($NUVL) current $123.57 share price.
- The firm lowered its price target on the biotech stock to $124 from a prior target of $172.
- Nuvalent shares recently trade around $123.57, sitting near the top of their 52-week range.
Get $NUVL trade alerts by text
We text you when insiders, Congress or big funds trade $NUVL. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Nuvalent, Inc. alert may contain errors. Disclosures
Bernstein Lowers Nuvalent Rating
On June 24, 2026, Bernstein adjusted its stance on Nuvalent, Inc. (NGM: NUVL), lowering its rating on the biotechnology company from a previous level to a market perform rating. Alongside the downgrade, the firm reduced its price target for the stock to $124 from a prior target of $172. The update reflects a revised outlook from the research firm as shares continue to trade near the upper end of their recent range.
Bernstein vs. the S&P 500
Hypothetical returns from Bernstein's disclosed trades, not real profit or advice. How we model this.
Nuvalent Stock Trades Near Highs
Nuvalent shares recently changed hands at $123.57 on Wednesday. The equity moves well above its 50-day moving average of $114.66 and its 200-day moving average of $105.26. The stock sits close to its 52-week high of $123.99, while its 52-week low stands at $71.13. With a market capitalization of roughly $9.81 billion, the clinical-stage firm carries a beta of 1.14, showing slightly higher volatility than the wider market.
$NUVL price target
Nuvalent, Inc. daily closes and this analyst's $124 target. Not advice.
Analysts Set New Price Targets
Following the update by Bernstein, the broader wall street sentiment for the clinical-stage firm remains cautious. Across the industry, nine analyst opinions shape the consensus for the equity, resulting in a recommendation key of hold. The average price target across those covering firms rests at $124, matching the new target set by Bernstein.
Inside Nuvalent's Pipeline
Nuvalent, Inc. operates as a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company focused on creating targeted therapies for cancer patients. The firm develops treatments such as zidesamtinib for ROS1-positive non-small cell lung cancer, neladalkib for ALK-positive tumors, and NVL-330 targeting HER2-driven tumors. Founded in 2017, the organization employs a team of 234 people and works alongside partners like Guardant Health to advance its research.
What to Watch at Nuvalent, Inc.
Investors will monitor upcoming clinical trial updates and future corporate disclosures from Nuvalent to gauge progress across its pipeline. Market participants should also look toward subsequent research notes from covering analysts to see if other firms adjust their targets following Bernstein's move.
Related Filing Alerts
Source: Bernstein's rating change on $NUVL (Jun 24, 2026). Written by software, not financial advice. How we make alerts